Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab  treatment in patients with severe chronic spontaneous urticaria

Ragıp ERTAŞ; Kemal ÖZYURT; Çiğdem KARAKÜKÇÜ; Muhammet Reşat AKKUŞ; Emin ÖZLÜ; Atıl AVCI; Mustafa ATASOY

Makale detayları

Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria

Yazarlar:

Ragıp ERTAŞ | Kemal ÖZYURT | Çiğdem KARAKÜKÇÜ | Muhammet Reşat AKKUŞ | Emin ÖZLÜ | Atıl AVCI | Mustafa ATASOY

Yayıncı:

TUBITAK

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Turkish Journal of Medical Sciences 2018 Vol.48 Issue 6, pp.1255-1262

Belge Tipi:

Makale

Yayın Tarihi:

12/2018

Belge Dili:

İngilizce

Document ID (Org No.):

2000750488

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

Özet:

 


                        Background/aim: 
Spontaneous wheals and/or angioedema lasting longer than six weeks are described as chronic spontaneous urticaria 
(CSU).  Omalizumab  is  used  for  the  treatment  of  antihistamine-resistant  CSU.  The  neutrophil-lymphocyte  ratio  (NLR),  platelet-
lymphocyte ratio (PLR), mean platelet volume (MPV), and platelet distribution width (PDW) are considered important indicators of 
inflammation and platelet activation in chronic diseases. 
We aimed to determine the NLR, PLR, MPV, and PDW levels in patients with CSU compared with healthy controls. We also aimed to 
investigate the effects of omalizumab therapy on these parameters in CSU patients. 
Materials and methods: 
This hospital-based, retrospective study included 143 patients with CSU and 132 healthy controls with a mean 
age of 40.0 ± 13.17 and 42.0 ± 16.34, respectively. Patients with equal or higher-than-baseline UAS scores at week 12 of omalizumab 
treatment  were  considered  nonresponders,  others  were  considered  responders.  We  analyzed  the  neutrophils,  lymphocytes,  platelet  
counts,  NLR,  PLR,  MPV,  and  PDW  before,  during,  and  after  omalizumab  treatment  and  compared  the  results  with  those  of  healthy  
controls. 
Results: 
CSU patients presented higher baseline MPV (P = 0.035) and lower baseline PDW values (P < 0.001) than healthy controls. 
There were statistically significant increases in the MPV (P < 0.001), MPV/platelet count (P 
= 
0.005), and PDW (P 
= 
0.003) and there 
was a statistically significant decrease in the NLR (P 
= 
0.018) during omalizumab treatment. The percent increase of MPV was low in 
nonresponders (P = 0.009). Nonresponders had lower PDW values than responders (P = 0.040).
Conclusion: 
The increase in the MPV and PDW may be due to platelet activation during omalizumab treatment. The decrease in the 
NLR may be regarded as an antiinflammatory effect of omalizumab. The effect of omalizumab on platelet and inflammatory markers 
may be used to discriminate the responders from nonresponders. 
                    

.

Makale detayları

Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria

Yazarlar: Ragıp ERTAŞ | Kemal ÖZYURT | Çiğdem KARAKÜKÇÜ | Muhammet Reşat AKKUŞ | Emin ÖZLÜ | Atıl AVCI | Mustafa ATASOY

Yayıncı: TUBITAK

Ana Başlıklar: Sağlık teşvikleri

Dergi: Turkish Journal of Medical Sciences 2018 Vol.48 Issue 6, pp.1255-1262

Belge Tipi: Makale

Yayın Tarihi: 12/2018

Belge Dili: İngilizce

Document ID (Org No.): 2000750488

Sıklık: İki Aylık

eISSN: 1303-6165

pISSN: 1300-0144

Sayı

Yazarlar:

Ragıp ERTAŞ | Kemal ÖZYURT | Çiğdem KARAKÜKÇÜ | Muhammet Reşat AKKUŞ | Emin ÖZLÜ | Atıl AVCI | Mustafa ATASOY

Yayıncı:

TUBITAK

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Turkish Journal of Medical Sciences 2018 Vol.48 Issue 6, pp.1255-1262

Belge Tipi:

Makale

Yayın Tarihi:

12/2018

Belge Dili:

İngilizce

Document ID (Org No.):

2000750488

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144